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Introduction
Working in the Critical Care Unit at
Grant Medical Center, many of our
patients admitted to the unit have a
history of Chronic Obstructive
Pulmonary Disease (COPD), and the
disease can complicate their course of
treatment. Working with this patient
population, it is common for these
patients to experience prolonged time
on the ventilator and increased length
of stay. Many patients have multiple
admissions throughout the year with
COPD exacerbation, thus decreasing
lung function and increasing risk for
mortality.
Chronic Obstructive Pulmonary Disease
is the third leading cause of death in
the United States and is affecting more
than 32 million Americans (Mosenifar,
2017). The prevalence of the disease
continues to rise and many people are
unaware they even have the disease.
Prevention is essential in decreasing
the incidence of the disease and
Advanced Practice Nurses (APN) play a
vital role. Chronic Obstructive
Pulmonary Disease (COPD) is a lung
disease characterized by progressive
airflow limitation resulting from smallairway disease and parenchymal
destruction (Burt & Corbridge, 2013).
The inflammation further weakens and
destroys the alveoli, thus decreasing
gas exchange. This collapse of lung
leads to air trapping and further
damage to the alveoli and narrowing of
the airway (Burt & Corbridge, 2013).
There are two types of COPD, chronic
bronchitis and emphysema.
Emphysema is abnormal permanent
enlargement of air spaces distal to the
terminal bronchioles, accompanied by
the destruction of alveolar walls and
without obvious fibrosis (Boka, 2016).
Being able to understand the
pathophysiology of emphysema will
allow for providers to accurately assess
patients and diagnosis the disease.
Educating patients and family
members about the disease and
providing preventative education such
as risk factors to the disease will help
prevent escalation of disease.

Pathophysiology

Image retrieved from: https://s-media-cacheak0.pinimg.com/736x/fb/d1/e3/fbd1e37e5350941d6050c211aacd81e0.jp
g

Classifications of Emphysema
There are three classifications for emphysema. They are classified
based off the region of injury. The three types include; centriacinar,
panacinar, and paraseptal (King Han, Dransfield, & Martinez, 2017).
1.
Centriacinar emphysema is mainly localized in the upper lung
zone and is the most common type of emphysema (Boka,
2016). This emphysema is specific to the proximal respiratory
bronchioles with focal destruction (Boka, 2016). Long term
cigarette smoking and dust inhalation are the most common
causes of this type
2.
Panacinar emphysema is mainly located in the lower half of the
lungs. This type of emphysema is usually present in individuals
who are alpha1-antitrypsin deficient (King Han, Dransfield, &
Martinez, 2017). In this type of emphysema, the entire alveolus
is destroyed (Boka, 2016).
3.
Paraseptal emphysema is mainly in the distal airway structures,
alveolar ducts, and alveolar sacs (Boka, 2016). The process of
destruction occurs near the septae of the lungs or pleura and is
at risk for spontaneous pneumothorax (Boka 2016).

There are two types of emphysema, primary and secondary emphysema.
Primary emphysema has a genetic component. Primary emphysema is an
autosomal recessive trait of alpha-1-antitrypsin deficiency. Alpha-1 antitrypsin
is a proteinase inhibitor and is made in the liver. This gene is a mutation in the
SERPINA1 gene located in the 14th chromosome. This protein helps protect the
lungs from damage. If not enough is made, then damage can occur and lead to
emphysema (Izaguirre Anariba, 2017). Secondary emphysema usually caused
by environmental factors, mainly from cigarette smoke, occupational and air
pollutants (Boka, 2016). Below discusses the pathophysiology behind
emphysema.
•
Foreign antigens infiltrate the lung epithelial cell barrier (Boka, 2016).
•
Inflammatory immune cells respond. These include polymorphonuclear
cells, eosinophils, macrophages, CD4, CD8 lymphocytes (Sharafkhaneh,
Hanania, & Kim, 2008).
•
The immune cells transport the antigens to the bronchial associated
lymphatic tissue layer (Boka, 2016).
•
Release of neutrophils, chemotactic factors occur (Boka, 2016).
•
Proteolytic enzymes are released mainly by macrophages, which destroys
the lungs epithelial barrier (Boka 2016).
•
Proteases and free radicals are released from neutrophils to further
damage the epithelial basement membrane (Boka 2016).
•
T lymphocytes in the sputum are mainly CD8 cells. These cells release
chemotactic factors to recruit more cells such as cytokines. This leads to
structural change to the lungs (Boka 2016).
•
Oxidative stress (produced form cigarette smoke and released from
inflammatory cells) and protease (produced by inflammatory,
macrophage, and epithelial cells) production further increases the
inflammation (Boka 2016).
•
Protease and anti-protease imbalance causes bronchiolar edema and
breakdown of lungs elastin (Boka 2016).
•
Thus, causing elastic fiber damage to the parenchyma, known as
emphysema (Burt & Corbridge, 2013).

Significance of Pathophysiology
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Understanding the importance of the pathophysiology and how it affects the individual
will help providers to understand the disease of emphysema. Below is the significance
of the pathophysiology of emphysema.
•
Inflammation decreases the elastic recoil of the lung tissue and destroys alveolar
attachments to small airways (Burt & Corbridge, 2013).
•
Reduction in alveoli with septal wall destruction reduces gas exchange and causes
the lung to collapse during expiration, thus limiting airflow (Berg, Joanne, &
Wright, 2016).
•
Bronchial inflammation increases pulmonary secretions, muscle contraction, loss
of alveolar supporting structure and airway edema causes airway narrowing or
obstruction (Burt & Corbridge, 2013)
•
When the airway is narrowed or obstructed, expiratory flow is decreased causing
hyperinflation of lung from small shallow breaths. (Burt & Corbridge, 2013)
•
Dyspnea occurs because the lungs are being overworked. (Burt & Corbridge, 2013)
•
Individuals will have the appearance of “barrel-chested” due to too much air
being trapped in the lungs (The Cleveland Clinic Foundation, 2017).
•
Further parenchymal destruction impedes gas exchange and leads to hypoxia.
(Burt & Corbridge, 2013)

Signs & Symptoms Implications for Nursing
The main sign of
Emphysema is dyspnea
(shortness of breath).
Many people who have
emphysema may
experience fatigue,
increased mucous
production, and wheezing
in the early stages. By the
time these symptoms
appear, often much of the
lung tissue has already
been destroyed. These
symptoms can often be
misdiagnosed for other
diseases or illnesses
(Cleveland Clinic
Foundation, 2017). The
disease usually progresses
where individuals will
experience increasing
shortness of breath that
affects their daily activities,
and eventually individuals
will experience shortness
of breath even at rest
(Mayo Clinic Staff, 2017).
Other symptoms include:
• Shortness of breath,
especially during light
exercise or climbing
steps
• Ongoing feeling of not
being able to get
enough air
• Long-term cough or
“smoker’s cough”
• Wheezing
• Long-term mucus
production
• Ongoing fatigue
• Chest tightness
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Education: The biggest risk factor is
smoking. Smoking cessation is the only
intervention shown to reduce the rate of
the disease progression and related to
mortality (Dolan, 2014). Providing patient
education about smoking cessation is
crucial to in advancing the stages of
emphysema and causing further damage.
Also, it is important to educate patients
about proper nutrition, exercise, correct
ways to use inhalers, and signs and
symptoms of exacerbations (Rennard &
Drummon, 2015).
Providing annual influenza vaccinations to
prevent exacerbation (Spencer & Hanania,
2013).
Patient diagnosing and monitoring:
Understanding many patients with
emphysema are older adults who have
many co-morbidities that can complicate
the management and treatment of
emphysema (Spencer & Hanania, 2013).
Prescribing appropriate medications for
patients with emphysema: Long-acting
bronchodilators are the recommended
therapy for patients with moderate to
severe COPD (Spencer & Hanania, 2013).
Corticosteroids are also another drug
therapy added to patients with moderate
to severe COPD. It is important to educate
the patients on side effects from their
medications they are prescribed (Spencer
& Hanania, 2013).
Evaluating treatment and how adherence
to treatment: Making sure patients are
following their treatment plan and have
appropriate knowledge of disease is
crucial. Patients may be discouraged about
disease, it is important for APN to provide
patients with realistic expectations of
treatment outcome and provide support to
patients and family members (Spencer &
Hanania, 2013).

Conclusion
APNs can play an important role in the
management of emphysema. It is crucial for
APNs to understand the pathophysiology of the
disease and the significance it plays in
individuals to better diagnose, treat, and
manage patients. Educating individuals about
disease and staying up to date on treatment
options will benefit both the APN and patient.

References
Berg, K., & Wright, J. L. (2016). The pathology of
chronic obstructive pulmonary disease.
Archives of Pathology & Laboratory Medicine,
140(12), 1423-1428.
Boka, K. (2016, August 31). Emphysema. Retrieved
June 28, 2017, from
http://emedicine.medscape.com/article/29828
3-overview#a5
Burt, L., & Corbridge, S. (2013). COPD exacerbations:
evidence-based guidelines for identification,
assessment, and management. American
Journal of Nursing, 113(2), 34-3.
https://doi.org/10.1097/01.NAJ.0000426688.96
330.60
Dolan, P. L. (2014). Preventing and treating COPD.
Medical Economics, 91(5), 54-58.
Izaguirre Anariba, D. E. (2017, February 10). Alpha1antitrypsin deficiency. Retrieved June 23, 2017,
from
http://emedicine.medscape.com/article/29568
6-overview#a5
King Han, M., Dransfield, M., & Martinez, F. (2017,
March 20). Chronic obstructive pulmonary
disease: definition, clinical manifestations,
diagnosis, and staging. Retrieved June 23, 2017,
from
http://www.uptodate.com/contents/chronicobstructive-pulmonary-disease-definitionclinical-manifestations-diagnosis-andstaging?source=search_result&search=emphys
ema&selectedTitle=1~150#H263049416
Mayo Clinic Staff. (2017, April 28). Emphysema.
Retrieved June 26, 2017, from
http://www.mayoclinic.org/diseasesconditions/emphysema/symptoms-causes/dxc20317007
Madell, R. (2013, March 26). Emphysema stages.
Retrieved June 20, 2017, from
http://www.healthline.com/healthslideshow/emphysema-stages#2
Mosenifar, Z. (2017, March 02). Chronic obstructive
pulmonary disease (COPD). Retrieved May 30,
2017, from
http://emedicine.medscape.com/article/29766
4-overview#a3
Rennard, S. I., & Drummond, M. B. (2015). Early
chronic obstructive pulmonary disease:
definition, assessment, and prevention. Lancet
(London, England), 385(9979), 1778–1788.
https://doi.org/10.1016/S0140-6736(15)60647X
Sharafkhaneh, A., Hanania, N. A., & Kim, V. (2008).
Pathogenesis of emphysema: from the bench
to the bedside. Proceedings of the American
Thoracic Society, 5(4), 475–477.
https://doi.org/10.1513/pats.200708-126ET
Spencer, P., & Hanania, N. A. (2013). Optimizing
safety of COPD treatments: role of the nurse
practitioner. Journal of Multidisciplinary
Healthcare, 6, 53–63.
https://doi.org/10.2147/JMDH.S35711
The Cleveland Clinic Foundation. (2017, May 26).
Emphysema symptoms & treatment | COPD.
Retrieved June 28, 2017, from
https://my.clevelandclinic.org/health/articles/e
mphysema

